Burning Rock Biotech (BNR) EBITDA Margin (2019 - 2026)

Burning Rock Biotech (BNR) has reported EBITDA Margin for 8 consecutive years, with 19.09% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA Margin fell 889.0% year-over-year to 19.09%; the TTM figure through Mar 2026 stood at 12.98% (up 3193.0% YoY), while the FY2025 annual figure was 11.02%, up 5551.0% from the prior year.
• EBITDA Margin came in at 19.09% for Q1 2026 at Burning Rock Biotech, down from 13.8% in the prior quarter.
• The five-year high for EBITDA Margin was 6.69% in Q2 2025, with the low at 195.13% in Q1 2022.
• Average EBITDA Margin over 5 years is 87.29%, with a median of 79.59% recorded in 2023.
• Across the five-year window, EBITDA Margin tumbled 4757 bps in 2022 and soared 10774 bps in 2024, its largest moves.
• Year by year, EBITDA Margin stood at 156.21% in 2022, then climbed by 13 bps to 136.47% in 2023, then surged by 56 bps to 59.74% in 2024, then surged by 77 bps to 13.8% in 2025, then sank by 38 bps to 19.09% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 19.09%, 13.8%, and 14.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.